Cargando…

P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES

Detalles Bibliográficos
Autores principales:	Pratz, Keith, Dinardo, Courtney, L Arellano, Martha, Thirman, Michael, Pullarkat, Vinod, S. Becker, Pamela, Douglas Smith, B., Zhang, Meng, E Werner, Michael, Potluri, Jalaja, A. Pollyea, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429562/ http://dx.doi.org/10.1097/01.HS9.0000969008.68978.fe

Ejemplares similares

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
por: Pollyea, Daniel A., et al.
Publicado: (2022)

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP
por: Pratz, Keith, et al.
Publicado: (2023)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study
por: Jonas, Brian A., et al.
Publicado: (2022)

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
por: Jonas, Brian A., et al.
Publicado: (2022)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021)

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
por: Chua, Chong Chyn, et al.
Publicado: (2022)

Venetoclax response prediction in acute myeloid leukemia: are we Finnish-ed with uncertainty?
por: Stevens, Brett, et al.
Publicado: (2023)

Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia
por: Pourhassan, Hoda, et al.
Publicado: (2022)

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018)

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
por: Stomper, Julia, et al.
Publicado: (2021)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy
por: Brackman, Deanna, et al.
Publicado: (2022)

Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

AML-337: Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy
por: Chang, Kyung Hee, et al.
Publicado: (2020)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2019)

Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
por: Zeidan, Amer M., et al.
Publicado: (2023)

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
por: Buettner, Ralf, et al.
Publicado: (2021)

Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
por: Zeidan, Amer M., et al.
Publicado: (2023)

Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine
por: Zhang, Alexander, et al.
Publicado: (2022)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
por: Zeidan, Amer M., et al.
Publicado: (2022)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

New directions for emerging therapies in acute myeloid leukemia: the next chapter
por: Daver, Naval, et al.
Publicado: (2020)

HMA6 and HMA8 are two chloroplast Cu(+)-ATPases with different enzymatic properties
por: Sautron, Emeline, et al.
Publicado: (2015)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective
por: Pratz, Keith W., et al.
Publicado: (2022)

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience
por: Trabal, Adriana, et al.
Publicado: (2023)

Recent advances in targeted therapies in acute myeloid leukemia
por: Bhansali, Rahul S., et al.
Publicado: (2023)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

Expression of HMA4 cDNAs of the zinc hyperaccumulator Noccaea caerulescens from endogenous NcHMA4 promoters does not complement the zinc-deficiency phenotype of the Arabidopsis thaliana hma2hma4 double mutant
por: Iqbal, Mazhar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_24h2ai3v68e9isqn4f96rl1vkp